#

Small caps

: 1296
Francesco Bergamini of Freedom24 Italy discusses four interesting European small-cap ideas / Photo: HJBC / Shutterstock.com
Small Caps·
Beyond the blue chips: Four European small caps deserving attention in 2H26
The companys new CEO said tough medicine is needed to reduce cash burn and achieve key milestones, and that Lucids full-year EV production and deliveries will fall short of current Wall Street estimates / Photo: Facebook / LucidMotors
Small Caps·
EV maker Lucid slumps on announced reorganization, delay in lower-cost model launch
Bitdeer has announced a 16-year colocation and services agreement with Volta for an AI and high-performance computing campus in Norway / Photo: Facebook / Bitdeerplatform
Small Caps·
Bitcoin miner Bitdeer inks major deal to lease data center capacity for Anthropic
Attovia is developing drugs using a licensed technology platform and patents, with one drug having completed dosing in a phase I trial and another expected to start trials in early 2027 / Photo: Unsplash / Mathurin Napoli / matnapo
Small Caps·
+1
·
Attovia IPO: Goldman-backed biotech debuts on the Nasdaq
If the drug is approved by the FDA, Compass plans to begin sales in the first half of 2027 / Photo: Compass / LinkedIn
Small Caps·
Compass could be first to U.S. market with psychedelics therapy for depression
The revision reflects concerns over the potential dilution of Birkenstock’s premium brand status amid changing consumer purchasing behavior in key markets / Photo: Facebook / Birkenstock
Small Caps·
Williams Trading downgrades Birkenstock as brand 'may be losing premium positioning'
Investment in quantum technology start-ups reached $12.6 billion in 2025, 6.3 times higher than in 2024, according to McKinsey / Photo: Germanru / Shutterstock.com
Small Caps·
Quantum small caps lost most of their 1H gains in July. Is the rally over?
Green Thumb continues generating profits while many rivals struggle, a Motley Fool analyst argues / Photo: Instagram / gtigrows
Small Caps·
Motley Fool calls Green Thumb the safest pot stock now, citing strong fundamentals
An FDA advisory panel voted that results from the study of Replimune’s experimental melanoma treatment are clinically meaningful / Photo: Replimune
Small Caps·
Biotech Replimune more than doubles after FDA panel OKs skin cancer treatment
A Cathie Wood ETF has invested in Scribe, a clinical-stage developer of gene therapies for heart diseases / Photo: Facebook / ARK Invest
Small Caps·
Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ
The record cybersecurity and IT modernization government contract is expected to add more than $5 million in annual recurring revenue for Cycurion / Photo: Cycurion
Small Caps·
IT small cap Cycurion soars 500% after landing biggest contract in its history
Apnimed raised $192 million in an upsized U.S. IPO, priced at the top of a marketed range / Photo: LinkedIn / Apnimed
Small Caps·
+1
·
Apnimed IPO: Sleep apnea drug developer debuts on the Nasdaq
Load more